98,483
Participants
Start Date
May 31, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
TZD only (RSG or PIO or troglitazone)
Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
TZD + spironolactone
"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
TZD + amiloride
"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
Lead Sponsor
GlaxoSmithKline
INDUSTRY